Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms, Lung: early-phase trial registry
1 of 3 indexed Neoplasms, Lung trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Neoplasms, Lung: 3 US clinical trials tracked, 1 recruiting.
Neoplasms, Lung is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Jerod L Stapleton, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition neoplasms-lung
OPEN 1 | RECR 33% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Neoplasms, Lung lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms, Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms, Lung is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Precision Lung Cancer Survivorship Care Intervention
Jerod L Stapleton, PhD
NCT05857995
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT04699188
A Phase I Study of iPS Cell Generation From Patients With COPD
Mayo Clinic
NCT01860898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms, Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms, Lung trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms, Lung page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Neoplasms, Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jerod L Stapleton, PhD sponsors the most Neoplasms, Lung trials on record, review their full trial history before evaluating a specific study. See Jerod L Stapleton, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms, Lung condition card totals 3 registered trials; most-linked intervention tislelizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.